Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Sintilimab in 2L+ SCLC
NCT04192682Phase 3Unknown
- Sponsor
- Changzhou Cancer Hospital of Soochow University
- Start
- May 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anlotinib and sintilimab in small cell lung cancer (SCLC), sponsored by Changzhou Cancer Hospital of Soochow University. Primary endpoint: Progress free survival at 1 year. Status: unknown.
02
Drugs
anlotinibsintilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04192682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04192682.